Chronic inflammation is a hallmark of neurodegenerative disease and cytotoxic levels of nitric oxide (NO) and pro-inflammatory cytokines can initiate neuronal death pathways. A range of cellular assays were used to assess the anti-inflammatory and neuroprotective action of resveratrol using murine microglial (C8eB4), macrophage (RAW264.7) and neuronal-like (Neuro2a) cell lines. We examined the release of NO by Griess assay and used a Bioplex array to measure a panel of pro-and anti-inflammatory cytokines and chemokines, in response to the inflammatory stimuli lipopolysaccharide (LPS) and interferon-g (IFNg).
Introduction
Chronic inflammation is known to be an important etiological condition for various chronic diseases, including atherosclerosis, diabetes, and arthritis. Furthermore, increasing evidence suggests that innate immune activation is a major component of age-related neurodegenerative diseases, such as Alzheimer's and Parkinson's disease (for recent reviews see (Heneka et al., 2014; Norden et al., 2015) ).
Inflammatory cells, including macrophages and microglia, play a major role in the body's response to immunogenic challenges, by re-establishing tissue homeostasis, producing large amounts of superoxide, nitric oxide (NO) and pro-inflammatory cytokines that aggravate and propagate inflammation and disrupt the normal function of cells. For example, the pro-inflammatory cytokine, tumour necrosis factor-a (TNF-a), binds to two tumour necrosis factor receptors TNFR1 and TNFR2 and, depending on the adaptor protein, activates various signalling pathways including nuclear factor-kB (NF-kB), and the mitogen activated protein kinases (MAPK), p38 and c-Jun N-terminal kinase (JNK), which can lead to proliferation, cell migration, apoptosis and necrosis (McCoy and Tansey, 2008) .
NO is a signalling molecule with diverse cellular roles; it is released by macrophages, neurons and endothelial cells and can be either protective or toxic to cells depending on the cellular context Gamper and Ooi, 2015) . The toxicity of NO is attributed to its ability to bind to proteins that contain heme, iron, copper or organic side groups, such as thiols, resulting in protein disruption and alterations in cellular activities. As a result of reactivity with a wide range of cellular components, high levels of NO are toxic to neurons, while low levels can be neuroprotective (Balez and Ooi, 2015) . Similarly there is evidence that activation of microglia could have a protective role in neurodegenerative diseases (Luo and Chen, 2012; Kan et al., 2015) . Therefore promoting anti-inflammatory cytokines or limiting pro-inflammatory cytokine and NO production by activated macrophages/microglia should be beneficial for prevention of systemic and local inflammation and would be potentially neuroprotective.
To date, pharmacotherapy of inflammatory conditions is based on the use of non-steroidal anti-inflammatory drugs (NSAIDs). However, NSAIDs can cause serious gastrointestinal toxicity such as gastric bleeding and the formation of stomach ulcers. Some NSAIDs, particularly cyclooxygenase-2 (COX-2) inhibitors, have been linked to increased blood pressure, greatly increased risk of congestive heart failure, thrombosis and myocardial infarction (Mitchell and Warner, 2006) . NSAIDs are inhibitors of cyclooxygenase and specifically suppress the production of prostaglandins (Vane et al., 1998) . Thus the identification of anti-inflammatory treatments with fewer adverse effects and drugs with broader anti-inflammatory properties is an important task. One such therapeutic approach involves suppressing the production of interleukin-1 (IL-1), TNF-a and other NF-kB regulated cytokines at the level of transcription, translation and/or secretion. The activities associated with certain of pyridinyl imidazoles involve a class of compounds referred to as cytokine suppressing anti-inflammatory drugs (CSAIDs) (Karunaweera et al., 2015) .
The stilbene resveratrol (3,4 0 ,5-trihydroxy-trans-stilbene) is a polyphenol CSAID found in grapes, red wine, mulberries knotweed, peanuts and other plants. Resveratrol dampens inflammation in arthritis (Elmali et al., 2007) and immune responsiveness in autoimmune disease (Singh et al., 2010) . Resveratrol can also penetrate the blood brain barrier in vivo (Baur et al., 2006) , however the effect of resveratrol on a broad range of pro-and anti-inflammatory factors has not previously been investigated.
In the present study, we first examined the expression of various pro-and anti-inflammatory cytokines, chemokines and NO by murine microglia (C8eB4) and macrophages (RAW264.7) in response to the inflammatory stimuli lipopolysaccharide (LPS) and interferon-g (IFN-g). We then determined the effects of resveratrol on cytokines and chemokines in activated C8eB4 microglia and RAW264.7 macrophages and investigated the effect of the preincubation time in cell culture on the calculated potency. Resveratrol potently inhibited the release of NO and a number of cytokines from activated macrophages and microglia and was able to protect neuronal-like Neuro2a cells from cytotoxic concentrations of NO. Conditioned media from activated RAW264.7 cells reduced the viability of Neuro2a cells, an effect that was prevented by pretreatment of the activated RAW264.7 cells with resveratrol. Together our results highlight the anti-inflammatory effects of resveratrol and its potential as a neuroprotective agent against neuroinflammation.
Materials and methods

Materials
The 23-multiplex cytokine assay was from Bio-rad (Gladesville, Australia). All cell culture materials were from Invitrogen (Mulgrave, Australia). Cell culture plasticware including Primaria plates was from Greiner Bio-One (Frickenhausen, Germany), Protease inhibitor cocktail, naphthyethylene-diamine, sulfanilamide, Corning
®
Costar
® Spin-X ® spin filter, LPS (from Salmonella enteric serotype thyphimurium), resazurin and S-Nitroso-N-acetyl-DL-penicillamine (SNAP) were from SigmaeAldrich (Castle Hill, Australia). Interferon-g was from Pepro Tech (Rocky Hill, USA). TrypLE Express™ was purchased from Life Technologies (Mulgrave, Australia). Cell lines were obtained from the ATCC.
Cell maintenance
RAW264.7, C8eB4 and Neuro2a cells were maintained in DMEM containing 25 mM glucose, supplemented with 200 U/ml penicillin, 200 mg/ml streptomycin, 200 mM glutamine (GlutaMax, Gibco) and 10% fetal bovine serum. Cells were grown in 75 cm 2 tissue culture flasks and incubated at 37 C in 5% CO 2 . RAW264.7 and Neuro2a cells were detached from the flask with a rubber policeman and split 1:10 every 5 days. C8eB4 cells were split 1:2 every 2 weeks and partial medium changes were performed twice a week.
Resveratrol treatment of LPS and IFN-g activated C8eB4 and RAW264.7 cells and SNAP-treated Neuro2a cells
Cells were washed twice with PBS and harvested with TrypLE Express. Cells were then plated in a 96-well plate at a density of 60,000 cells/well and incubated for 24 h before treatment. Cells were pre-treated with resveratrol for 1 h before adding the activation mix containing 12.5 mg/ml LPS and 5 Units IFN-g for 24 h. The total volume of medium in each well was 100 ml and to obtain enough supernatant for further analysis, the supernatant from 3 wells was combined. The supernatant was spin filtered (0.2 mm Corning spin filter) and 0.4 ml protease inhibitor cocktail containing Aprotinin, Bestatin, EÀ64, Leupeptin and Pepstatin A (Sigma) was added. Fifty microlitres of supernatant was immediately used for measuring NO and the remainder was stored at À80 C for later analysis by cytokine array. Neuro2a cells were pre-treated with resveratrol for 1 h before treatment with the NO donor, SNAP, at concentrations ranging from 0.1 to 1000 mM or the vehicle control (DMSO). Cells were harvested for cell viability assays and the supernatant collected for Griess assay to measure nitrite concentration.
2.4. Neuro2a incubation with conditioned media from activated RAW264.7 cells As in Section 2.3 RAW264.7 cells were plated at a density of 60,000 cells/well and incubated for 24 h before treatment.
RAW264.7 cells were activated with 12.5 mg/ml LPS and 5 Units IFNg for 24 h. Cells were pre-treated with 100 mM resveratrol or vehicle control (DMSO) for 1 h prior to inflammatory activation. Neuro2a cells were seeded at a density of 60,000 cells per well in a 96-well plate, and incubated for 24 h. Media from RAW264.7 cells were added to Neuro2a cells. As a further control, Neuro2a cells were also pre-treated with 100 mM resveratrol or vehicle control (DMSO) for 1 h prior to application of RAW264.7 conditioned media. After 24 h of incubation with conditioned media from RAW264.7 cells, the Neuro2a cells were assessed by cell viability and Griess assay. The same measurements were simultaneously taken for the RAW264.7 cells.
Resazurin-based assay for determination of cell viability
Cell viability was assessed in terms of the metabolic capability of cells to convert the non-fluorescent redox indicator, resazurin, into its highly fluorescent product, resorufin. DMEM (100 ml) containing 0.125 mg/l resazurin was added to each well of a 96-well plate and incubated for 90 min a 37 C. Fluorescence was measured at 560 nm excitation/590 nm emission using a BMG Labtech POLARstar Omega fluorescent plate reader (BMG LABTECH, Ortenberg, Germany).
Nitrite determination by Griess assay
The nitrite concentration in the culture medium was measured as an indicator of NO production using the Griess reaction. Supernatant from each well (50 ml) was transferred to a fresh 96 well plate and 25 ml of 1% sulfanilamide plus 25 ml of 0.1% napthyethylene-diamine in 5% HCl were added. When combined, these compounds (known as Griess reagent), form a violet colour in the presence of nitrite. After 10 min incubation at room temperature, the absorbance of each well was measured at 540 nm using a Bio-Rad Model 680 Microplate reader (Bio-Rad, Gladesville, Australia). Nitrite concentration was calculated with reference to a standard curve of sodium nitrite generated by known concentrations, ranging from 0 to 100 mM.
Determination of cytokine levels using a Bioplex cytokine assay
A panel of 23 cytokines was measured, using a Bioplex Pro™ mouse cytokine 23-plex kit (Bio-Rad, Gladesville, Australia), according to the manufacturer's protocol.
Data analysis
The standard error of the mean (SEM) and all other values were calculated from at least three independent experiments. Significant differences were assessed by one-way ANOVA with Tukey's multiple comparisons test. IC 50 values for resveratrol were calculated using the sigmoidal doseeresponse function.
Results
LPS and IFN-g activation increases NO and cytokine/chemokine release in murine RAW264.7 and C8eB4 cells
For the determination of the potency of a CSAID, cell lines with a broad range of cytokine and chemokine response are needed. These cell lines should react upon stimulation with pro-inflammatory stimuli, such as LPS and IFN-g, with up-regulation of inducible nitric oxide synthase (with resulting NO production and release), as well as increased expression and release of pro-inflammatory cytokines such as TNF-a, interleukin-1a (IL-1a), IL-1b, IL-6, IL-12, as well as chemokines such as granulocyte colony-stimulating factor (G-CSF).
When both cell lines were activated with a combination of LPS and IFN-g, a significant increase in NO production (determined as nitrite) was observed. The activated macrophage cell line RAW264.7 released approximately four times more NO compared to C8eB4 cells (Table 1 ). In addition, 17 different inflammatory markers were determined using the Bioplex Pro™ mouse cytokine 23-plex immunoassay (6 markers were below detection threshold; Table 1 ).
In both cell lines, activation with LPS and IFN-g for 24 h led to a significant up-regulation of the pro-inflammatory cytokines IL-1a, IL-6, TNF-a, IL-12(p40) and the chemokines G-CSF and CeC motif chemokine 5 (CCL5, also known as RANTES). Activation also upregulated the anti-inflammatory cytokines IL-10 and IL-13 in RAW264.7 macrophage cells but not in C8eB4 microglia. The chemokines monocyte chemotactic protein 1 (MCP-1), macrophage inflammatory protein-1a (Mip-1a), Mip-1b, were also only upregulated in RAW 264.7, but not in C8eB4 microglia. In general, the C8eB4 cells showed a more limited cytokine/chemokine release repertoire than the RAW264.7 cells under the same activation conditions (Table 1) .
Resveratrol prevents NO and cytokine release in RAW264.7 and C8eB4 cells but has a limited effect on chemokine release
To answer the question as to whether resveratrol possesses broad anti-inflammatory actions, cells were pre-incubated with resveratrol at concentrations up to 100 mM for 1 h prior to activation by LPS and IFN-g in RAW264.7 and C8eB4 cells, after which the release of NO, cytokines and chemokines was measured. Only those pro-inflammatory markers that had shown an up-regulation of >1.5 fold in the previous experiment were analysed. An antiinflammatory effect of resveratrol (defined as an IC 50 value < 100 mM) could be demonstrated in both cell lines. Resveratrol down-regulated the pro-inflammatory cytokines IL-1a, IL-1b, IL-6 and TNF-a in both RAW264.7 and C8eB4 cells. However, it also down-regulated the anti-inflammatory cytokine IL-10 in RAW264.7 cells only (Table 2) . Resveratrol effects on chemokines were more limited, leading to down-regulation of only MCP-1 and RANTES in RAW264.7 (Table 3) .
Increasing pre-incubation time marginally increases potency of resveratrol
Since the effects of inflammatory activation were more potent in the RAW264.7 cells and since resveratrol was more effective in limiting inflammatory activation of RAW264.7 cells, we continued our experiments using this cell line only. One of the most fundamental questions to judge the clinical efficacy of a compound is whether the concentration of the compound in the human body is in the same order of magnitude as its IC 50 value. However, it might be possible that some cell culture experiments are also conducted under suboptimal conditions, and effective concentrations are higher than needed. For example, a very short pre-incubation time might make it impossible or difficult for the compound to reach an intracellular target, whereas long pre-incubation times might lead to substantial degradation of the compound.
We wanted to determine whether our experimental setup of 1 h pre-incubation time affected potency, resulting in limited diffusion of resveratrol into the cell. We hypothesized that the calculated potency might increase when the incubation time was extended. To answer this question, RAW264.7 cells were pre-incubated with resveratrol for 1, 3, 6, 9 and 24 h before activation with LPS and IFNg. NO was measured after 24 h to assess the potency of resveratrol.
In these experiments the calculated IC 50 decreased from 44.7 ± 7.1 mM after 1 h pre-incubation to 26.7 ± 3.5 mM after 6 h preincubation, increasing after 24 h pre-incubation (Fig. 1) . To exclude the possibility that the decrease in the release of the proinflammatory markers were caused by cell death, cytotoxicity of resveratrol was measured in RAW264.7 and C8eB4 cells. At preincubation times of 1 h, and concentrations below 100 mM, resveratrol did not show cytotoxicity in RAW264.7 cells. Only at a concentration of 110 mM did resveratrol cause a decrease in cell viability by 13% in C8eB4 cells (data not shown). The LC 50 values (lethal concentration at which 50% of the cells were killed) remained the same in all pre-treatment ranges but increased only after 24 h pre-treatment (Table 4 ). The increase in NO production at 24 h pre-treatment was therefore likely due to an increase in cell number following 24 h pre-incubation. Our data suggest that the calculated potency of resveratrol increases 1.6 fold with increasing pre-incubation times and this is not due to an alteration in cell viability.
Resveratrol protects Neuro2a cells from cytotoxic levels of NO
The neuroprotective and neurodegenerative capacity of inflammatory cells are central to understanding pathways pertinent to neuronal survival. Identifying molecules that promote neuronal survival is central to preventing neurodegeneration. The simplest way to study these effects is to remove contributing factors and study one component of the system. To determine whether resveratrol could be neuroprotective against cytotoxic concentrations of NO, Neuro2a cells were treated with 1 mM resveratrol for 6 h prior to incubation with the NO donor, SNAP. This concentration was chosen based on our previous experiments in Neuro2a cells and because resveratrol reaches nanomolar to micromolar concentrations in the plasma and brain (Nguyen et al., 2013; Walker et al., 2014) . SNAP incubation at concentrations of 0.1 and 1 mM did not increase nitrite levels above vehicle control, as measured by Griess assay (no significant difference from control). SNAP at concentrations of 10, 100 and 1000 mM increased nitrite levels in Neuro2a media by 4, 15 and 100 fold, respectively (Fig. 2) , with no significant difference in nitrite levels measured in the media from cells treated with resveratrol compared to control. Concentrations ranging from 0.1 to 100 mM SNAP had no effect on Neuro2a cell viability, while 1000 mM SNAP was neurotoxic, reducing cell viability by 22 ± 5% (p < 0.05, n ¼ 3; Fig. 3 ) compared to vehicle control. Even at the lowest concentration of resveratrol tested in macrophages and microglia (1 mM) resveratrol was able to protect Neuro2a against cytotoxic concentrations of NO and nitrosative stress (Fig. 3) . Resveratrol increased cell viability in the presence of 10, 100 and 1000 mM SNAP by 2.7, 2.9 and 2.1 fold, respectively, and was thus able to prevent the cytotoxic effects of 1000 mM SNAP.
Since resveratrol was able to protect cells against cytotoxic concentrations of NO, we further investigated its potential as a neuroprotective agent. The neuroprotective effect of resveratrol was tested in a macrophage-neuron co-culture experiment using the transfer of conditioned media, as described previously (Münch et al., 2003) . Media were incubated with RAW264.7 cells for 24 h and then incubated with Neuro2a cells. RAW264.7 cells were pretreated with 100 mM resveratrol or vehicle control (DMSO) for 1 h prior to inflammatory activation and activated with 12.5 mg/ml LPS and 5 Units IFN-g for 24 h, as in the previous experiments. Media from RAW264.7 cells were added to Neuro2a cells and after 24 h incubation cell viability and Griess assays were performed for the RAW264.7 and Neuro2a cells. As expected, inflammatory activation of RAW264.7 cells led to a dramatic up-regulation of nitrite in the media of RAW264.7 cells (Fig. 4A) . Nitrite remained at similar levels 24 h after transfer of the media to the Neuro2a cells (Fig. 4B) . Preincubation of the RAW264.7 cells with 100 mM resveratrol prevented increases in nitrite that remained present in the media that was transferred to the Neuro2a cells and incubated for 24 h (Fig. 4A,  B) . Resveratrol treatment alone on RAW264.7 (without inflammatory activation) had no effect on the viability of Neuro2a cells (Fig. 5A) . Conversely, inflammatory activation of RAW264.7 led to a reduction in Neuro2a viability that was reduced by pre-incubation of RAW264.7 with resveratrol. As further controls, media containing the inflammatory mixes, with or without resveratrol were added direct to the Neuro2a cells in the absence of incubation with RAW264.7 cells (Fig. 5B) . Application of this media had no significant effect on viability of Neuro2a cells in any of the conditions, showing that the reduction in Neuro2a viability was caused by molecules secreted by activated RAW264.7 cells. In addition, Neuro2a cells were pre-treated with 100 mM resveratrol or vehicle control (DMSO) for 1 h prior to application of RAW264.7 conditioned media (Figs. 4 and 5) . This treatment had no further effect on nitrite levels or Neuro2a viability, suggesting that the neuroprotective effects observed were specifically due to the antiinflammatory effects of resveratrol on RAW264.7 cells. Together these data highlight the potential neuroprotective role for the action of resveratrol via its anti-inflammatory actions, in addition to its ability to protect against cytotoxic levels of NO.
Discussion
4.1. RAW264.7 macrophages exhibited a more reactive phenotype than C8eB4 microglia, releasing higher levels of nitric oxide and pro-inflammatory cytokines During brain inflammation, the microglia proliferate and migrate to the inflammatory lesion (Kettenmann et al., 2011) . Blood derived macrophages may also enter the brain via the blood brain barrier. (Guillemin and Brew, 2004) . In the central nervous system two different macrophage populations have a role to play in supporting neurons, and these are often described as CNS-resident microglia and CNS-infiltrating peripheral macrophages. In neurodegenerative diseases, such as Alzheimer's disease, CNS-infiltrating peripheral macrophages may contribute to neurodegeneration, however activated microglia may also protect neurons by removing toxic aggregates and cellular debris (Kraft and Harry, 2011) . Functional differences in CNS-resident microglia and acutely infiltrating inflammatory macrophages have been identified (Carson et al., 2007) . Thus an understanding of cell-type specific effects and the differences in commonly used cellular models of macrophages and microglia is important to identify the roles these cells play in neuroprotection/neurodegeneration (Simard et al., 2006) . Activated microglia behave similarly to macrophages by inducing cytotoxicity in a variety of cells through the release of NO (Brantley et al., 2010) . It is likely that some microglia develop from a pool of blood monocytes and colonize the brain early in development (Lawson et al., 1990 (Lawson et al., , 1992 . Evidence suggests that LPS and IFN-g-activated microglia isolated from the adult brain are more similar to macrophages infiltrating the CNS than naive microglia of the brain (Schmid et al., 2009 ). Therefore it is important to consider the responses of each of these cell types to activation and the effects of any neuroprotective agents in preventing these responses. To address this we have carried out a comprehensive study on the anti-inflammatory effects of resveratrol, a polyphenol 26.7 ± 3.5 152.6 ± 20.5 9 28.0 ± 3.6 141.9 ± 29.8 24 53.6 ± 17.4 249.4 ± 165.4
Fig. 2. Quantitation of nitrite following incubation with the NO donor SNAP.
Neuro2a cells were incubated with 1 mM resveratrol or vehicle control for 6 h prior to treatment with vehicle or 0.1, 1, 10, 100 or 1000 mM of the NO donor SNAP and incubated for 24 h. Nitrite levels in the cell media were measured by Griess assay. Data shown are mean ± SEM, n ¼ 3. Fig. 3 . The effects of the NO donor SNAP on cell viability following pre-treatment with resveratrol. Neuro2a cells were incubated with 1 mM resveratrol or vehicle control for 6 h prior to treatment with vehicle or 0.1, 1, 10, 100 or 1000 mM of the NO donor SNAP and incubated for 24 h. Cell viability was measured by resazurin assay. Data shown are mean ± SEM, n ¼ 3. Significant interactions were determined by twoway ANOVA; # denotes p < 0.05 SNAP treatment compared to vehicle control; * denotes p < 0.05 resveratrol treatment compared to vehicle control. present in grape skin, artichoke and basil, with purportedly neuroprotective actions (reviewed in (Jayasena et al., 2013) ). To study the effects of resveratrol we compared macrophage and microglial cell lines during activation by LPS and IFN-g. Both cell lines expressed a panel of pro-inflammatory cytokines following activation, though C8eB4 microglial cells were more limited in their repertoire. RAW264.7 macrophages released higher levels of 15 out of 17 cytokines tested and four times as much NO (measured as nitrite) compared to C8eB4 microglial cells. Therefore RAW264.7 macrophages show a more reactive phenotype than C8-B4 cells following activation with the same concentrations of LPS and IFN-g.
Resveratrol exhibits anti-inflammatory properties
Resveratrol reduced 7 out of 9 pro-inflammatory cytokines from C8eB4 cells and 5 out of 9 pro-inflammatory cytokines from RAW264.7 cells. It also significantly reduced nitrite levels in both lines, but had a more limited effect on chemokine release, reducing only MCP-1 and RANTES in macrophages. Additionally, resveratrol treatment did also reduce the anti-inflammatory cytokine IL-10. However our experiments also showed that resveratrol protects against pro-inflammatory or cytotoxic molecules released into the media by activated macrophages. Importantly the concentrations of resveratrol that had an identifiable anti-inflammatory effect are consistent with concentrations that can be found in the plasma (mM levels) (Walker et al., 2014) . In addition it is likely that resveratrol metabolites, including resveratrol-3-sulfate also possess antiinflammatory activities that could provide further antiinflammatory activity (Walker et al., 2014) .
Consistent with our findings, resveratrol reduced the levels of IL-6, NO, and TNF-a in RAW264.7 cells (Yang et al., 2014) . In this study, the expression levels of high mobility group protein B1 and toll-like receptor 4 were reduced following resveratrol treatment, hinting at potential mechanisms involved in these antiinflammatory effects. Our study builds on these findings providing a comprehensive view of the down-regulation of cytokines by resveratrol. A previous study identified that resveratrol similarly down-regulated MCP-1 mRNA, to reduce foam cell formation, potentially through up-regulation of AMP-activated protein kinase (AMPK) and sirtuin-1 (Dong et al., 2014) . Our data together with that of others is therefore generating a picture of the broad anti-inflammatory actions of resveratrol. Such broad and potent anti-inflammatory activities have led to proposals of resveratrol treatment for diverse conditions, including cancer (Jang et al., 1997) , pain (Gentilli et al., 2001) , neurodegenerative disease (Virgili and Contestabile, 2000) , obesity (Baur et al., 2006) , diabetes (Su et al., 2006) , rheumatoid arthritis (Elmali et al., 2007) and depression (Xu et al., 2010) . However, there are also examples in which resveratrol dietary supplementation worsened clinical severity, for example in viral and autoimmune mouse models of multiple sclerosis (Sato et al., 2013) , suggesting that resveratrol would make a poor option for therapeutic treatment of demyelinating diseases. In addition, our data suggest that there is a narrow therapeutic window for resveratrol with higher levels contributing to cytotoxicity. The design of the study focuses on the protective effects of resveratrol in reducing pro-inflammatory cytokines and the release of soluble cytotoxic factors but it must also be noted that there are many putative beneficial biological roles of activation of these cells. For example, activation of microglia allows the removal of toxic aggregates and cellular debris and the effects of resveratrol in vivo must be tempered with the possibility that local immune suppression contributes to neurodegeneration (Kan et al., 2015) . Similarly, as a counter to the reductions in pro-inflammatory cytokines by resveratrol treatment, it must be noted that resveratrol also inhibited the release of the anti-inflammatory cytokine, IL-10, and had a limited effect on chemokine release. A recent study using hippocampal astrocytes identified a role for resveratrol in downregulating TNF-a, IL-1b, IL-6 and IL-10 in astrocytes following LPS activation (Bellaver et al., 2015) . The mechanisms identified were similar to those in neurons and involved NF-kB, p38 and MAPK signalling (Bellaver et al., 2015) . Other mechanisms proposed for the protective effects of resveratrol in primary astrocytes are reviewed in (Quincozes-Santos and Gottfried, 2011). For example, changes in glutamate handling (Vieira de Almeida et al., 2007) and protection via the activation of nuclear factor erythroid 2-related factor 2 (Erlank et al., 2011) , a transcription factor that protects astrocytes against glutathione reduction and oxidative stress (Steele et al., 2013a (Steele et al., , 2013b have been implicated. Future in vivo studies and co-culture experiments will help to delineate the specific roles of individual cytokines and chemokines in distinct cell types in mediating neurodegenerative and neuroprotective mechanisms.
Effects of resveratrol in vivo and its potential as a neuroprotective agent
An in-depth study of the levels of inflammatory markers in humans following resveratrol ingestion has not yet been carried out. However, consistent with our findings of a large downregulation of pro-inflammatory molecules, a small study using an extract of Polygonum Cuspidatum (containing 40 mg resveratrol) taken daily for 6 weeks did lead to the reduction of plasma concentrations of TNF-a and IL-6 (Ghanim et al., 2010) . In a recent study in a mouse model of familial Alzheimer's disease, long-term resveratrol treatment reduced amyloid and prevented memory loss, potentially via activation of sirtuin-1 and AMPK signalling pathways (Porquet et al., 2014) . Surprisingly this occurred even following an increase in IL-1b and TNF-a. Potent anti-inflammatory activity for resveratrol has now been identified in a number of disease models in mice, including reduced lung inflammation through increasing superoxide dismutase, glutathione peroxidase, and catalase activity by enhancing nuclear translocation of NF-kB and heme oxygenase-1 activity . Multiple mechanisms for the neuroprotective activity of resveratrol have been identified (reviewed in (Renaud and Martinoli, 2014) ). Suggested mechanisms for resveratrol in protecting neurons against Alzheimer's disease include by preventing oxidative stress and toxic amyloid aggregation (Ladiwala et al., 2010; Shariatizi et al., 2015) and this could occur by augmentation in the expression and activity of anti-oxidant enzymes, such as catalase and superoxide dismutase (Sadi and Konat, 2015) . Other findings have highlighted a mechanism of action for resveratrol in activating sirtuin-1 to inhibit p53 transcription and enhance neuroprotection (Feng et al., 2015) or via MAPKs, NF-kB and nicotinamide adenine dinucleotide phosphate-oxidase (NADPH oxidase) signalling pathways .
We have previously shown that resveratrol has pro-energetic effects in Neuro2a cells with the ability to increase ATP and GTP levels in the cells (Nguyen et al., 2013) . In line with this, resveratrol increased cell viability, an effect that was most evident in cells treated with high levels of the NO donor but not in the absence of NO (Figs. 2, 4 and 5) . NO is a potent activator of AMPK and in turn AMPK protects cells against the damaging effects of NO; in pancreatic b cells this mechanism involves activation of inositol-requiring enzyme 1 (Meares et al., 2011) . During disruption of energy homeostasis AMPK is activated by an increased AMP/ATP ratio (Sanders et al., 2007) . In pancreatic b cells AMPK activation by NO improved metabolic function of b-cells to prevent cell death following NO treatment (Sanders et al., 2007) . Resveratrol did not increase the energy charge potential (a measure of energy status of the cell) of Neuro2a cells in conditions of sufficient nutrition but only during starvation conditions (Nguyen et al., 2013) . Our current results suggest that resveratrol is also protective under conditions of nitrosative stress in Neuro2a cells. Our data do not support a role for resveratrol in direct scavenging of nitric oxide (Figs. 2, 4 and 5) but rather suggest it promotes a cytoprotective pathway. Thus it is possible that resveratrol promotes cell survival of Neuro2a cells against NO-mediated cell death via the activation of AMPK, in addition to its antiinflammatory effects.
An important issue in considering resveratrol as a potential neuroprotective agent is whether it can exert functional effects in the brain following peripheral administration or ingestion. In line with this consideration, brain inflammation caused by streptozotocin injections induced cognitive impairment in rats, yet memory performance was enhanced following peripheral resveratrol administration (Sharma and Gupta, 2002) . In mice, resveratrol administration upregulated sirtuin-1 to protect neurons against neurodegeneration in models of Alzheimer's disease and motor neurone disease (Kim et al., 2007) . These findings have now been confirmed in adult primates, in which dietary resveratrol treatment (200 mg/kg/day) for 18 months increased working memory and cognitive performance (Dal-Pan et al., 2011) . Importantly, these studies have recently been extended to humans and a picture of the neuroprotective effects of resveratrol in aging adults is emerging. Following 26 weeks of resveratrol intake (200 mg/day) older adults showed significant increases in hippocampal functional connectivity and memory performance, demonstrating an increased retention of words (Witte et al., 2014) . We have studied the effects of nitric oxide and inflammation on Neuro2a cell viability. Technical developments in generating the many distinct cell types of the brain using induced pluripotent stem cells will provide a more accurate model of the human nervous system in vitro . Future studies will capitalise on these advancements to identify the contribution of distinct cell types and molecular mechanisms involved in neuroprotection and neurodegeneration.
Conclusions
The findings from our study suggest that resveratrol has broad anti-inflammatory effects and is capable of down-regulating proinflammatory responses in cellular models of both CNS-resident microglia and CNS-infiltrating peripheral macrophages. Our findings provide further evidence of the neuroprotective potential of resveratrol during neuroinflammation.
